Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide significant associations were observed with 84 variants all located at the known PrCa risk regions at 8q24 (128.484-128.548) and 10q11.22 (MSMB gene).
|
31226226 |
2020 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Additionally, 6 pathways were identified based on identified variants and genes, including estrogen signaling pathway, signaling by MST1, IL-15 production, MSP-RON signaling pathway, and IL-12 signaling and production in macrophages, which are known to be associated with prostate cancer.
|
31748686 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Plasma MSP concentrations were inversely associated with prostate cancer risk after adjusting for total prostate-specific antigen concentration [odds ratio (OR) highest versus lowest fourth of MSP = 0.65, 95% confidence interval (CI) 0.51-0.84, Ptrend = 0.001].
|
31089709 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hitherto, these conditions have been not studied in Mexico yet, neither if sexually transmitted infections could modify the MSMB and PC association.
|
30774776 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 31 proteins were associated with prostate cancer risk including proteins encoded by <i>GSTP1</i>, whose methylation level was shown previously to be associated with prostate cancer risk, and <i>MSMB, SPINT2, IGF2R</i>, and <i>CTSS</i>, which were previously implicated as potential target genes of prostate cancer risk variants identified in genome-wide association studies.
|
31337649 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results of our study suggest that combined PSP94/PTEN analysis can be potentially used in the clinical prognosis of prostate cancer.
|
31516752 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data revealed that the T allele of MSMB rs10993994 polymorphism was significantly associated with PCa in all subjects (allele contrast: OR=1.24, 95% CI=1.19-1.29, p<0.001).
|
31773691 |
2019 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
MSMB levels are also reduced in the circulation and MSMB is therefore used as a serum biomarker for prostate cancer.
|
29250809 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
We also review the diagnostic assays that are developed for PSP94 for use in the diagnosis of PCa and use of such tests in the differential diagnosis of PCa from benign prostatic hyperplasia (BPH).
|
28930560 |
2018 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data also demonstrated that HGF/c-Met, but not the MSP-RON signaling pathway may be the dominant mechanism for PCa EMT.
|
28440432 |
2017 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
We assessed the performance of a 4-kallikrein panel with and without microseminoprotein-β to predict high grade (Gleason 7+/Gleason Grade Group 2+) prostate cancer on biopsy in a multiethnic cohort from PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial).
|
27810449 |
2017 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, this meta-analysis indicates that MSMB gene rs10993994 polymorphism increases the risk of PC.
|
28212531 |
2017 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our objective was to determine the gene expression pattern of the SFRP family in prostatic cell lines and fresh frozen tissues from normal prostates (NP), benign prostatic hyperplasia (BPH) and prostate cancer (PCa), by qRT-PCR, and their DNAme status by MSP and bisulfite sequencing.
|
27570179 |
2016 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Across 66 meta-analyses, a total of 20 genetic variants involving 584,100 subjects in 19 different genes (KLK3, IGFBP3, ESR1, SOD2, CAT, CYP1B1, VDR, RFX6, HNF1B, SRD5A2, FGFR4, LEP, HOXB13, FAS, FOXP4, SLC22A3, LMTK2, EHBP1 and MSMB) exhibited significant association with prostate cancer.
|
26967244 |
2016 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this report, individual domains of prostate cancer related biomarkers; MSMB and PSA were overexpressed in bacterial system and purified in their folded forms using affinity chromatography.
|
27038170 |
2016 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
The methylation of GSTP1 and RASSF1A was investigated by using the MSP in 50 prostate cancer and 17 benign prostate hyperplasia specimens.
|
25577235 |
2015 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
A peak at m/z 10,760 was identified as β-microseminoprotein (β-MSMB) and found to be statistically lower in urine from PCa participants using the peak's average areas.
|
24115268 |
2014 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
GWASDB |
Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
|
24753544 |
2014 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Another novel mechanism, which we propose in this review article, is that PSP94 may protect against prostate cancer by preventing or limiting an intracellular fungal infection in the prostate.
|
24464504 |
2014 |
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.
|
23484134 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the increase in PC risk associated with rs10993994:C>T is likely mediated by the variant's effect on PSP94 expression; however, this effect does not extend to NCOA4 in the data presented here.
|
22887727 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of prostate cancer susceptibility variant (MSMB) rs10993994 with risk of spermatogenic failure.
|
23608167 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR analysis revealed that MSMB, NBL1 and AZGP1 were expressed with much higher specificity in PCa and NP than in 14 other kinds of normal tissue.
|
22948749 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Regardless of race and ethnicity or rs10993994 genotype, men with low blood levels of MSP have increased risk of prostate cancer.
|
23213189 |
2013 |
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The rs10993994 genotype in the MSMB gene modifies the association between number of sexual partners and PCa risk.
|
24037734 |
2013 |